Latanoprost etkileşimleri

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage. (Ketorolak etiketi, Kontrendikasyonlar)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Atenolol etiketi, İlaç etkileşimleri)

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Atenolol ve klortalidon etiketi, İlaç etkileşimleri)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Diflunisal etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Diklofenak etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Etodolak etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fenoprofen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Flurbiprofen etiketi, Uyarılar ve önlemler)

Indomethacin Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. (Furosemid etiketi, İlaç etkileşimleri)

Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Hidrokodon ve ibuprofen etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (İbuprofen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (İbuprofen ve famotidin etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (İndometazin etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Mefenamik asit etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Meloksikam etiketi, Uyarılar ve önlemler)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (Metilergometrin etiketi, İlaç etkileşimleri)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Nabumeton etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Naproksen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Naproksen ve esomeprazol etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Oksaprozin etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Piroksikam etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Salsalat etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Selekoksib etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. (Sulindak etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Sumatriptan ve naproksen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Tolmetin etiketi, Uyarılar)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Potasyum klorür etiketi, İlaç etkileşimleri)